Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Ardelyx revenue
Ardelyx's revenue is $333.6 million.
What is Ardelyx's revenue?
- Ardelyx's revenue growth from 2013 to 2024 is 1,053.26%.
- Ardelyx has 86 employees, and the revenue per employee ratio is $3,879,244.
- Ardelyx's peak quarterly revenue was $116.1M in 2024(q4).
- Ardelyx peak revenue was $333.6M in 2024.
- Ardelyx annual revenue for 2023 was 124.5M, 138.61% growth from 2022.
- Ardelyx annual revenue for 2024 was 333.6M, 168.06% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Ardelyx historical revenue
Ardelyx's peak revenue was $333.6M in 2024. The peak quarterly revenue was $116.1M in 2024(q4).
Ardelyx's revenue increased from $28.9m in 2013 to $333.6M currently. That's a 1,053.26% change in annual revenue.
Ardelyx annual revenue
Ardelyx annual revenue over time
| Fiscal year / year | Ardelyx revenue |
|---|---|
| 2013 | $28.9M |
| 2014 | $31.6M |
| 2015 | $24.0M |
| 2017 | $42.0M |
| 2018 | $2.6M |
| 2019 | $5.3M |
| 2020 | $7.6M |
| 2021 | $10.1M |
| 2022 | $52.2M |
| 2023 | $124.5M |
| 2024 | $333.6M |
How accurately did Ardelyx's revenue projections match actual performance?
Ardelyx annual growth
Ardelyx saw the greatest revenue growth in 2022, when revenue increased by 416.57%.
Ardelyx had the lowest revenue growth in 2018, when revenue changed by -93.79%.
Ardelyx annual growth rate over time
| Year | Ardelyx growth |
|---|---|
| 2014 | 9%↑ |
| 2015 | -24%↓ |
| 2017 | 75%↑ |
| 2018 | -94%↓ |
| 2019 | 103%↑ |
| 2020 | 43%↑ |
| 2021 | 33%↑ |
| 2022 | 417%↑ |
| 2023 | 139%↑ |
| 2024 | 168%↑ |
Ardelyx quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Ardelyx quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2014 | - | $9.1M | $7.6M | $6.3M |
| 2015 | $5.9M | $18.1M | - | - |
| 2017 | - | - | - | $42.0M |
| 2018 | $2.3M | $30,000 | $172,000 | $85,000 |
| 2019 | - | $18,000 | $3.0M | $2.3M |
| 2020 | $1.2M | $1.8M | $2.7M | $1.8M |
| 2021 | $6.6M | $1.3M | $1.2M | $1.0M |
| 2022 | $468,000 | $2.5M | $5.0M | $44.2M |
| 2023 | $11.4M | $22.3M | $56.4M | $34.4M |
| 2024 | $46.0M | $73.2M | $98.2M | $116.1M |
Ardelyx jobs nearby
Do you work at Ardelyx?
Is Ardelyx transparent about its revenue structure?
Ardelyx financial information
| CEO | Michael G. Raab |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 86 |
| Date Founded | 2007 |
| Headquarters | Fremont, California |
| Number of Locations | 2 |
| Revenue | $333.6M |
| Net Income | -$67,207,000 |
| Gross Proft | $283.1M (2024) |
| PE Ratio | -2.80 |
| Tax Rate | -0.0% |
| Market Capitalization | $109.4M |
| Total Assets | $190,066,000 |
| Ticker | ARDX |
Ardelyx jobs you might like
Ardelyx financing
Ardelyx received early financing of $26.1M on 2008-06-12.
| Series | Round size | Date |
|---|---|---|
| Series A | $26M | 06/2008 |
| Debt Financing | $5M | 11/2010 |
| Series B | $30M | 08/2011 |
| Post Ipo Equity | $77.8M | 06/2015 |
| Post Ipo Equity | $110M | 07/2016 |
| Post Ipo Debt | $50M | 05/2018 |
| Post Ipo Debt | $27.5M | 02/2022 |
Ardelyx investors
| Investors | Security type |
|---|---|
| CMEA Capital | Series A |
| New Enterprise Associates (NEA) | Series B |
| CMEA Capital | Series B |
| Amgen Inc. | Series B |
| New Enterprise Associates (NEA) | Post Ipo Equity |
| Broadfin Capital | Post Ipo Equity |
| Cormorant Asset Management | Post Ipo Equity |
| Sabby Capital | Post Ipo Equity |
| Foresite Capital | Post Ipo Equity |
| RA Capital Management | Post Ipo Equity |
| Rock Springs Capital | Post Ipo Equity |
| EcoR1 Capital LLC | Post Ipo Equity |
| New Enterprise Associates (NEA) | Post Ipo Equity |
| QUADRILLE CAPITAL | Post Ipo Equity |
| Deerfield | Post Ipo Equity |
| Cormorant Asset Management | Post Ipo Equity |
| Perceptive Advisors | Post Ipo Equity |
| RA Capital Management | Post Ipo Equity |
| Rock Springs Capital | Post Ipo Equity |
| First Manhattan Consulting Group | Post Ipo Equity |
| Dafna Capital Management | Post Ipo Equity |
| SLR Capital Partners | Post Ipo Debt |
Ardelyx competitors
Ardelyx's top competitor, OPKO Health, earned an annual revenue of $713.1M.
Ardelyx's smallest competitor is Minerva Biotechnologies with revenue of $2.4M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| OPKO Health | - | $713.1M | 6,096 | - |
| Ambrx | - | $7.4M | 80 | - |
| Ophthotech | - | $210.0M | 58 | - |
| Achaogen | - | $8.7M | 42 | - |
| Global Blood Therapeutics | - | $194.7M | 457 | - |
| Minerva Biotechnologies | - | $2.4M | 24 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Ardelyx, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Ardelyx. The employee data is based on information from people who have self-reported their past or current employments at Ardelyx. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Ardelyx. The data presented on this page does not represent the view of Ardelyx and its employees or that of Zippia.
Ardelyx may also be known as or be related to ARDELYX INC., ARDELYX, INC., Ardelyx, Ardelyx Inc and Ardelyx, Inc.